Put Hims 3-in-1 Hard Mints in its own comparison column. It describes the 3-in-1 chew listing sildenafil, tadalafil and vitamin B12, rather than every treatment sold by Hims. A useful comparison keeps the medicine, the supply and the payment interval together. Otherwise a cheaper-looking figure may describe a different formula or a larger commitment.
Availability: Public product listing; individual eligibility and current prescription require confirmation.
The exact product
The first comparison field is the actual preparation. The material distinction here is two ED drugs plus a vitamin, rather than three ED drugs. Match every active ingredient and dosage form before looking at timing or unit cost. Products with similar names can contain different drugs; products with the same drug can use different formulations. Neither resemblance establishes interchangeability. The identity table is a record of the provider's listing, not a prescription-selection tool.
| Provider | Hims |
|---|---|
| Listed active ingredients | Sildenafil + tadalafil + vitamin B12 |
| Dosage form | Compounded mint-flavored chew |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Hims: current ED treatment catalog · Hims: Hard Mints formulation safety library · Hims: Hard Mints chewable ED medicines |
Price, supply and payment
The quoted public price is From $30/month in the ED catalog. Treat the details below as the boundaries of that quote. Only calculate a unit figure when both the charge and the supplied quantity belong to the same offer; only calculate a monthly equivalent when the payment term is known. A blank quantity or renewal price should remain blank. Comparing invented complete totals is less reliable than explaining why two published offers cannot yet be matched.
| Current catalog headline | From $30/month |
|---|---|
| Separate chewable-page offer | Selected sildenafil/tadalafil mints from $6/use |
| Price limitation | The two headlines do not establish a five-chew plan |
| Name limitation | Other Hard Mints formulations have different active ingredients |
What the research can support
Evidence is another comparison field, not a bonus point for a more complicated formula. This product's relevant evidence includes ingredient and regimen research; Hims user surveys are not trials of this exact chew. The missing comparison concerns the matching quantity, strengths and upfront payment. A valid superiority claim would need a suitable comparator and outcome, not merely different marketing language. Record whether the source measured erection outcomes, subjective preference, absorption or something else before treating a percentage or timing claim as comparable.
| Evidence boundary | ingredient and regimen research; Hims user surveys are not trials of this exact chew |
|---|---|
| Not established here | the matching quantity, strengths and upfront payment |
| Clinical and regulatory references | Cui et al. (2015): daily tadalafil with as-needed sildenafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil · MedlinePlus: Tadalafil |
Safety questions for the prescriber
Cost matching does not establish clinical suitability. A clinician must review nitrates, recreational nitrites, riociguat, other ED drugs, blood-pressure treatment and relevant medical history before prescribing. Do not try to recreate Hims 3-in-1 Hard Mints with cheaper separate medicines. A do-it-yourself combination can create a new exposure without reproducing the studied or prescribed preparation. The specific safety distinction below can change which comparisons are meaningful for an individual.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|---|
| Added nutrients | Review actual amounts and duplicate supplements; nutrient inclusion does not prove improved ED efficacy. |
Availability and the actual prescription
There is little value in ranking a price for an offer you cannot select. Our access finding is: Public product listing; individual eligibility and current prescription require confirmation. Account restrictions and a medical eligibility decision are different filters. Obtain confirmation of the exact current product before comparing cancellation rules or moving away from an existing plan. A product page that remains reachable is evidence of public documentation, not a guarantee of inventory or enrollment.
Refills, changes and cancellation
Add a change-of-treatment row to the budget. Ask whether a new formula requires another assessment, a replacement supply or a separate charge, and whether the current order can still be stopped. For the clinical side, use “Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve?” The two answers should come from the appropriate teams. A support agent's billing explanation does not settle medication safety, and a clinical message does not necessarily stop automatic processing.
| Next charge | The next order date is the charge/processing date; a first refill can be scheduled early. |
|---|---|
| Cancellation notice | At least 48 hours before the next order, according to support guidance. |
| Already processing | Ending a subscription does not cancel an order already processing or shipped. |
| Refund boundary | No refund guaranteed after pharmacy processing. |
| Policy sources | Hims Support: canceling a subscription · Hims Support: refund policy · Hims Support: when billing occurs |
Compare named products
The alternatives below are selected because they share an ingredient, format or clinical question. They are not ranked by efficacy. Compare them using the same columns: complete ingredients, supplied form, prescribed schedule, quantity, amount due and renewal. If one column remains unknown, identify that limitation in the comparison rather than awarding the offer a value advantage based on a starting banner.
Questions to keep with the offer
The decision-ready comparison is a written quote plus a prescribing explanation. The public records for Hims 3-in-1 Hard Mints can narrow the questions but cannot provide those personal answers. No test purchase, clinical trial or pharmacy inspection was performed for this review. Sources identify advertised facts and evidence limits; commercial presentation elsewhere on this publication is not a clinical score.
| Ask about this formula | Why does this prescription combine both PDE5 inhibitors, and what role does B12 serve? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
Check the source
Public pages checked October 7, 2026. Provider material establishes advertised terms, not independently verified clinical results.
- Hims: current ED treatment catalogProvider catalog; individual named offers and starting prices
- Hims: Hard Mints formulation safety libraryProvider formulation document; includes options not confirmed in the main catalog
- Hims Support: canceling a subscriptionProvider policy; 48-hour notice and orders already processing
- Hims Support: refund policyProvider policy; no guaranteed refund after pharmacy processing
- Hims Support: when billing occursProvider policy; next order date, charge timing, and subscription intervals
- Hims Support: changing the next order dateProvider support; refill rescheduling differs from cancellation
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- Hims: Hard Mints chewable ED medicinesProvider source; compounded formulations and advertised starting prices
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products
- MedlinePlus: TadalafilDrug information; standard tadalafil products